Market Overview - The Hong Kong stock market showed mixed performance today, with the Hang Seng Index closing flat at 26,545.1 points and a total turnover of HKD 3,768.12 million. The Hang Seng China Enterprises Index rose by 0.17% to 9,472.35 points, while the Hang Seng Tech Index increased by 0.37% to 6,294.42 points. For the week, the Hang Seng Index gained 0.59%, the China Enterprises Index rose by 1.15%, and the Tech Index saw a 5.09% increase [1]. Blue Chip Performance - Sands China (01928) led the blue-chip stocks, rising by 6.19% to HKD 21.6, contributing 4.77 points to the Hang Seng Index. The upcoming National Day and Mid-Autumn Festival holidays have driven demand for gaming stocks, with strong expectations for the Golden Week based on nearly full hotel bookings [2][4]. - Other notable blue-chip performers included China Hongqiao (01378) up 4.67% to HKD 26.46, Galaxy Entertainment (00027) up 4.22% to HKD 42.46, while Hansoh Pharmaceutical (03692) fell by 2.62% to HKD 35, dragging the index down by 1.74 points [2]. Sector Highlights Gaming Sector - The gaming sector saw significant gains, with Melco International Development (00200) up 6.6%, Sands China (01928) up 6.19%, and Wynn Macau (01128) up 6.02%. Macau's gross gaming revenue (GGR) for August reached MOP 22.16 billion, marking a new monthly high, with a year-on-year increase of 12.2% [3][4]. Gold Sector - Gold stocks rebounded, with Shandong Gold (01787) rising by 6.13% to HKD 35.68, Lingbao Gold (03330) up 3.98% to HKD 16.46, and Zijin Mining (02899) up 2.76% to HKD 29.08. The price of spot gold has stabilized above USD 3,650 following the Federal Reserve's interest rate cuts [4]. Coal Sector - Coal stocks performed well, with Yanzhou Coal Mining (01171) up 6.51% to HKD 10.63, and China Shenhua Energy (01088) up 1.42% to HKD 38.46. Recent investigations into overproduction in Inner Mongolia are expected to curb excess supply [5][6]. Robotics Sector - The robotics sector showed mixed results, with Sanhua Intelligent Control (02050) down 6.21% while DCH Holdings (00179) rose by 5.78%. Recent rumors regarding Tesla's robot orders were denied by Elon Musk, but the Chinese government is pushing for the application of humanoid robots in various industries [7]. Notable Stock Movements - Jinfang Pharmaceutical-B (02595) debuted with a remarkable increase of 106.47% to HKD 42.1. The company focuses on developing new treatment solutions for tumors and autoimmune diseases [8]. - Hongteng Precision (06088) surged by 21.44% to HKD 5.89, benefiting from Nvidia's investment in Intel for AI infrastructure [9]. - Cloudfin Financial (00376) rose by 10.55% to HKD 6.39 after appointing a former Ant Group executive to lead its Web3 development [10]. - Weimob Group (02013) increased by 10% to HKD 2.86 following a significant share placement [11]. - Ganfeng Lithium (01772) saw a rise of 9.51% to HKD 37.3, with the company announcing full production capacity for its energy storage cells [12]. - Changfei Optical Fiber (06869) reached a new high, increasing by 8.55% to HKD 61.6, driven by interest in hollow core fiber technology [13][14].

Market Overview - The Hong Kong stock market showed mixed performance with the Hang Seng Index closing flat at 26,545.1 points and a total turnover of HKD 37.68 billion. The Hang Seng China Enterprises Index rose by 0.17% to 9,472.35 points, while the Hang Seng Tech Index increased by 0.37% to 6,294.42 points. For the week, the Hang Seng Index gained 0.59%, the China Enterprises Index rose by 1.15%, and the Tech Index increased by 5.09% [1] Blue Chip Performance - Sands China (01928) led blue-chip stocks with a rise of 6.19% to HKD 21.6, contributing 4.77 points to the Hang Seng Index. The upcoming National Day and Mid-Autumn Festival boosted demand for gaming stocks, with strong expectations for the Golden Week based on nearly full hotel bookings [2][4] - Other notable blue-chip performances included China Hongqiao (01378) up 4.67% to HKD 26.46, and Galaxy Entertainment (00027) up 4.22% to HKD 42.46 [2] Sector Highlights Gaming Sector - The gaming sector saw significant gains, with Melco International Development (00200) up 6.6% and Wynn Macau (01128) up 6.02%. Macau's gaming revenue reached MOP 22.16 billion in August, marking a 12.2% year-on-year increase [3][4] Gold Stocks - Gold stocks rebounded, with Shandong Gold (01787) rising 6.13% to HKD 35.68. The price of spot gold rose above USD 3,650 following the Federal Reserve's interest rate cut, with long-term gold investment still seen as valuable due to ongoing economic concerns [4] Coal Sector - The coal sector performed well, with Yanzhou Coal Mining (01171) up 6.51% to HKD 10.63. Recent investigations into overproduction in Inner Mongolia are expected to stabilize coal production levels [5][6] Robotics Sector - The robotics sector showed mixed results, with Sanhua Intelligent Control (02050) down 6.21% while Delta Electronics (00179) rose 5.78%. Recent news regarding Tesla's plans for humanoid robots has created volatility in this sector [6] Notable Stock Movements - Jinfang Pharmaceutical-B (02595) debuted with a remarkable increase of 106.47% to HKD 42.1, focusing on cancer and autoimmune disease treatments [7] - Hongteng Precision (06088) surged 21.44% to HKD 5.89, benefiting from Nvidia's investment in Intel for AI infrastructure [8] - Cloud Financial (00376) rose 10.55% to HKD 6.39 after appointing a former Ant Group executive to lead its Web3 development [9] - Weimob Group (02013) increased by 10% to HKD 2.86, announcing a share placement to raise approximately HKD 1.555 billion [10] - Ganfeng Lithium (01772) saw a rise of 9.51% to HKD 37.3, with full production capacity in energy storage cells and ongoing developments in solid-state batteries [11] - Yangtze Optical Fibre and Cable (06869) reached a new high, increasing by 8.55% to HKD 61.6, driven by interest in hollow-core fiber optics [12]

Core Viewpoint - The company has announced a share buyback plan totaling up to HKD 10 billion, in addition to a completed buyback of HKD 3.87 billion, indicating a strong commitment to returning value to shareholders [1] Group 1: Share Buyback Details - The company completed a share buyback of HKD 3.87 billion in the first half of 2024 [1] - The board has approved an additional share buyback plan of up to HKD 10 billion [1] - As of September 19, approximately HKD 7.73 billion has been utilized to repurchase a total of about 164 million shares [1] Group 2: Future Buyback Plans - Starting from September 19, the company plans to repurchase up to HKD 50 billion in shares over the next 24 months, excluding the previously mentioned HKD 10 billion [1] - The repurchased shares will be canceled [1]

Group 1 - The Hong Kong stock market is experiencing weakness, but southbound funds are significantly buying in, with a net purchase amount exceeding 4 billion [1] - The Hang Seng China Enterprises ETF (159960) has seen a slight increase of 0.1%, with mixed performance among constituent stocks; JD.com (09618) leads with a rise of 3.13%, while NetEase (09999) falls by 2.41% [1] - The Federal Reserve announced a 25 basis point cut in the federal funds rate target range to between 4.00% and 4.25%, with expectations of an additional 50 basis points cut by year-end [1] Group 2 - According to China Merchants Securities, the Hong Kong market is primarily driven by liquidity, and with ample internal and external liquidity, a new round of increases is expected [1] - Factors contributing to the easing of liquidity constraints in September include the Fed's rate cut, improved funding conditions in Hong Kong, continuous inflow of southbound funds, and the resolution of profit concerns following interim reports [1] - The Hang Seng China Enterprises Index (HSCE) includes major companies such as Alibaba (09988), Tencent (00700), and Xiaomi (01810), with the top ten stocks accounting for 55.76% of the index [2]

Core Viewpoint - The Hong Kong Stock Connect Innovation Drug ETF (520880) is experiencing volatility, with a recent trend of price fluctuations and a potential influx of buying interest as the market adjusts [1][3]. Group 1: Market Performance - The ETF has seen a decline in its constituent stocks, with only three out of 37 companies showing slight gains, while major stocks like InnoCare Pharma and Innovent Biologics have dropped significantly [3]. - The ETF has attracted over 670 million yuan in inflows over the past 13 days, indicating strong investor interest despite market fluctuations [4]. - The ETF's index has shown a year-to-date increase of 119.75% before recent adjustments, outperforming other innovation drug indices [6]. Group 2: Industry Insights - The ETF manager attributes the recent adjustments to multiple factors, including a lack of major business development catalysts and ongoing regulatory concerns from the Trump administration regarding Chinese innovation drugs [3]. - The manager emphasizes the importance of maintaining focus on the biopharmaceutical sector, suggesting that current market corrections may present buying opportunities for high-quality innovation drug companies [3]. - The ETF has undergone a "purification" process, removing CXO companies and focusing solely on innovation drug research and development, which is expected to enhance its performance in future market rallies [5][6].

Core Viewpoint - The stock price of pharmaceutical company Yaojie Ankang experienced extreme volatility, with a trading range of nearly 124% on September 16, raising questions about the inclusion of the stock in index funds without prior notice [1][2][6]. Group 1: Stock Performance - Yaojie Ankang's stock price surged by 10 times within seven trading days starting from September 8, reaching a peak of 679.5 HKD per share before plummeting by 53.73% to 192 HKD per share on September 16 [2][3]. - The stock experienced further fluctuations, with an 8.96% increase on September 17, followed by a 12.43% decline on September 18 [2][6]. Group 2: Index Inclusion and ETF Impact - Yaojie Ankang was added to the Hong Kong Stock Connect list on September 8, coinciding with the start of its stock price volatility [3]. - Multiple ETFs tracking the National Index for Hong Kong Stock Connect Innovative Drugs experienced significant declines following Yaojie Ankang's stock price drop, with some ETFs falling over 2% on September 16 and 17 [6][8]. - The National Index's website had not updated the sample adjustments as of September 18, leading to confusion regarding the timing of Yaojie Ankang's inclusion in the index [6][9]. Group 3: Industry Concerns - Industry experts questioned the rapid inclusion of Yaojie Ankang in the index, as it did not meet the criteria of having a significant trading volume over the past year [9][10]. - The lack of prior announcement regarding the stock's inclusion raised concerns about the passive nature of index funds, which could lead to investors inadvertently buying at inflated prices [8][11]. - There is a call for improved index design and communication to prevent similar situations in the future, emphasizing the need for transparency in the inclusion process [10][11].

来源：市场资讯 （来源：ETF万亿指数） 美联储降息终于落地了降。 25bp符合预期，点阵图显示年内还要降两次，有点鸽派；但是鲍威尔的表态又"不够鸽派"，so，有点纠 结。 所以，涨跌都有理，有句话说的好，符合预期就是利好兑现，跌。 对了，还有Good Afternoon的梗... 如果鲍威尔说"Good Afternoon"，就是偏鹰派，不降息或者降息没超预期，跌。 如果他说"Hello Everyone"，那就是鸽，要降息，涨！ 华尔街机构也早早的部署好了AI系统，第一时间捕捉到他舌头的微小变化，来决定买卖了... 有点失望的是，鲍威尔这回的开场是"Good Afternoon"。 自这之后，美股先涨后跌，大A似乎也复制了同样的走势，不得不服啊这预判。 那，今天聊聊降息下，大家比较关注的创新药板块，调整后还没有没有机会。 一、创新药，三重压力下暂时回调 港股通创新药ETF（520880）在连续9个交易日调整后，场内却延续高频溢价，买盘资金依然强势，这 辆创新药高速列车是否在等待更多人上车？ 港股通创新药ETF基金经理丰晨成解读，近期调整主要源于三重因素叠加： 1、行业催化空窗期：缺乏大BD（商务拓展）催化 ...

Core Viewpoint - Maiwei Biotech has signed exclusive licensing and preferred stock purchase agreements with Kalexo Bio, Inc. for the 2MW7141 project, which could yield up to $1 billion in upfront and milestone payments, along with low single-digit royalties [1][2]. Group 1: Company Overview - Maiwei Biotech's stock price increased by over 10% following the announcement, reaching a peak increase of 13.21% [1]. - The company is focused on developing dual-target small nucleic acid drugs, with 2MW7141 aimed at managing dyslipidemia and preventing high-risk cardiovascular events [2][5]. - The 2MW7141 project is currently in the CMC (Chemistry, Manufacturing, and Controls) development stage, and specific drug targets have not been disclosed due to confidentiality [1][5]. Group 2: Partnership Details - The agreement with Kalexo allows for exclusive global development, production, and commercialization rights for the 2MW7141 project [2]. - Kalexo, established in December 2023, is an innovative drug company created by AditumBio, which focuses on accelerating new drug development through capital and expertise [2][3]. - The potential total transaction value for the partnership is higher than previous collaborations, with Maiwei Biotech receiving an upfront payment of $12 million and milestone payments contributing to the total of up to $1 billion [3]. Group 3: Industry Context - The cardiovascular disease sector is highly competitive, with major pharmaceutical companies actively pursuing small nucleic acid therapies [5]. - Existing therapies, while effective, still leave room for improvement in reducing disease indicators, which the dual-target approach of 2MW7141 aims to address [5]. - Recent collaborations in the industry, such as the one between Boehringer Ingelheim and Novartis, highlight the trend of strategic partnerships focusing on early-stage projects in the small nucleic acid space [5][6].

来源：新浪基金∞工作室 9月18日，港股创新药ETF（159567）收盘涨0.21%，成交额25.65亿元。 港股创新药ETF（159567）成立于2024年1月3日，基金全称为银华国证港股通创新药交易型开放式指数 证券投资基金，基金简称为港股创新药ETF。该基金管理费率每年0.50%，托管费率每年0.10%。港股创 新药ETF（159567）业绩比较基准为国证港股通创新药指数收益率(经估值汇率调整)。 规模方面，截止9月17日，港股创新药ETF（159567）最新份额为81.71亿份，最新规模为77.68亿元。回 顾2024年12月31日，港股创新药ETF（159567）份额为3.95亿份，规模为3.78亿元。即该基金今年以来 份额增加1966.63%，规模增加1956.03%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 流动性方面，截止9月18日，港股创新药ETF（159567）近20个交易日累计成交金额377.58亿元，日均 成交金额18.88亿元；今年以来， ...

CSPC PHARMACEUTICAL GROUP LIMITED 石藥集團有限公司 （根據公司條例在香港註冊成立） (Stock Code: 1093) （股份代號：1093） NOTIFICATION LETTER 通知信函 Dear Non-registered holder (Note) , CSPC Pharmaceutical Group Limited (the "Company") — Notice of Publication of 2025 Interim Report (the "Current Corporate Communications") The English and Chinese versions of the Current Corporate Communications are available on the Company's website at www.cspc.com.hk and the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk. If you would ...